Carbon-11-methionine and PET in evaluation of treatment response of breast cancer

R. Huovinen1,2, S. Leskinen-Kallio1,2, K. Nägren1, P. Lehikoinen1, U. Ruotsalainen2 & M. Teräsv1

1Department of Oncology and Radiotherapy, Turku University Central Hospital, 20520 Turku; 2Turku Medical Cyclotron-PET Center, c/o Department of Nuclear Medicine, Turku University Central Hospital, 20520 Turku; 3Radiochemistry Laboratory, Turku University, 20500 Turku, Finland.

Summary Uptake of L-methyl-11C-methionine (11C-methionine) in breast cancer metastases was studied with positron emission tomography (PET). Eight patients with soft tissue metastases were studied twice: before the onset of chemotherapy (4), hormonal therapy (3) or radiotherapy (1) and 3–14 weeks later. The radioactivity concentration of the low molecular weight fraction of venous plasma samples separated by fast gel filtration was used as input function. The input corrected uptake rate of 11C-methionine (K) in breast cancer metastases before the treatment ranged between 0.035 and 0.186 min−1 and the standardised uptake value (SUV) between 2.0 and 11.4. The uptake of 11C-methionine into the metastases decreased when clinical objective stability or regression of the metastases was later obtained and increased in cases where progressive disease was seen during treatment. We conclude that metabolic changes in the amino acid metabolism detected by PET precede the clinical response, and may be of clinical value in predicting the treatment response.

In oncology the evaluation of treatment response to cancer therapy is a fundamental issue and is usually aided by radiological or nuclear imaging. Positron emission tomography (PET) has opened a totally new approach in evaluating metabolic changes in cancer tissue caused by chemotherapy or radiotherapy in vivo. Using a glucose analogue 18F-2-fluoro-2-deoxy-D-glucose (FDG) and PET imaging may be a valuable method in predicting treatment response in head and neck cancer (Minn et al., 1988), breast cancer (Minn & Soini, 1989) and lung cancer (Abe et al., 1990). Active metabolism may be visualised by radiotracers such as FDG or L-methyl-11C-methionine (11C-methionine) which take part in altered turnover of glucose or amino acids in cancer tissue (Kubota et al., 1985; Wahl et al., 1991).

Methionine is necessary in cancer cells for increased protein and polyamine synthesis and in transfmyelination reactions. This essential amino acid has a central role in the altered metabolism of malignant cells (Hoffman, 1990). The amino acid metabolism of cancer tissue can be studied in vivo by measuring uptake of 11C-methionine by PET. The uptake has been reported to decrease rapidly as a response to radiation therapy in an experimental tumour model (Kubota et al., 1989) and to bromocriptine treatment in pituitary adenomas (Bergström et al., 1987).

We studied the uptake of 11C-methionine in breast cancer metastases to find out whether the change in the uptake during cancer therapy could predict the clinical response to treatment.

Materials and methods

Patients

Eight patients with breast cancer who had progressive metastatic disease were consented to undergo a PET study. The study was approved by the Ethical Committee of Turku University Central Hospital. Only patients with soft tissue metastases were accepted to the study; five patients with supraclavicular or axillary lymph node metastases, two with pleural and one with pulmonary metastases. All patients studied were included in the analysis. PET scanning was performed twice with each patient: before the onset of the new therapy and 3–14 weeks later (median 7 weeks). Patient 1 (Table I) received palliative radiation therapy (megavoltage therapy 40 Gy). Three patients were treated with hormone therapy: Patient 2 received high dose toremifene (anti-estrogen) treatment, patient 3 tamoxifen and patient 8 medroxyprogesterone acetate. Four patients received chemotherapy: Patients 4 and 5 received combination of cyclophosphamide, metotrexate and fluorouracil and patients 6 and 7 received weekly low dose epipodorubicin. Patients 3, 4 and 5 were studied under their first therapeutic intention, patients 6 and 2 under their second therapeutic intention, patients 1 and 7 under their fourth therapeutic intention and patient 2 under her ninth therapeutic intention (Table I).

The size of the metastases was recorded at the time of the first PET study, the time of the second PET study and finally 3–6 months after the beginning of the therapy, at which time the clinical response was evaluated according to the criteria of WHO (Miller et al., 1981). The maximal diameter of the palpable lymph node metastases ranged from 2 to 5 cm except one axillary lymph node with a diameter of 7 cm (Table I, patient 1). The maximal diameter of the thickest part of the two pleural metastatic processes was 3 cm on chest X-ray (Table I, patients 2 and 3) and that of the pulmonary hilus metastasis was 3 cm on chest X-ray (Table I, patient 3). The size of the metastases did not change significantly during the interval between the two PET studies except in the case of the 7 cm axillary lymph node metastasis, which shrunk to 5 cm in diameter. Duration of the response and survival of the patients was evaluated after 2 years from the PET study.

PET imaging

The patients had a light protein-poor breakfast 3 to 4 h before PET scanning. An ECAT Scanner type 931/08-12 was used for PET imaging. The device acquires 15 contiguous slices simultaneously with a slice thickness of 6.7 mm; the transaxial full width half maximum is 6.1 mm in the center of the field of view (Spinks et al., 1988).

11C-methionine was synthesized at the Turku University Radiochemistry Laboratory as described elsewhere (Längström et al., 1987). The purity of 11C-methionine was higher than 92.5%, except in two studies, where it was 82.0% (study I of patient 6) and 89.0% (study II of patient 8). The remaining radioactivity was mainly in the form of 11C-methionine sulphoxide as discussed elsewhere (Nägren, 1992). Prior to emission scan, a transmission scan was carried out using a retractable ring source containing 68Ge. This entailed a 15 min scan,

Correspondence: R. Huovinen, Department of Oncology and Radiotherapy, Turku University Central Hospital, 20520 Turku, Finland. Received 10 February 1992; and in revised form 30 October 1992.
of the clavicular region and a 20–25 min scan for the trunk. \(^{11}\)C-methionine (160–320 MBq) was injected into an upper extremity vein. After the injection, the dynamic emission scanning was carried out for 60 min the frame times being 4 × 30 s, 3 × 60 s, 5 × 180 s, 4 × 300 s and 2 × 60 s.

**Blood sampling**

Frequent venous blood samples were taken during the emission scanning from a cubital vein contralateral to the injection site. A total of 17 blood samples were taken, ten of which during the first 3 min after the injection. To ease the blood sampling the arm was first heated with a pad. The radioactivity concentration of the plasma samples was determined. The low molecular weight fraction of plasma samples, which consists mainly of \(^{11}\)C-methionine, taken at 10, 20, 40 and 60 min after the injection was separated by fast gel filtration (Sephadex PD-10 columns, Pharmacia Fine Chemicals, Sweden) and the radioactivity concentration was determined for curve fitting.

**ROI analysis**

One or more regions of interest (ROIs) in two to three planes were drawn on the hot spots in the tumour. The size of the ROIs was restricted to the highest accumulation area and was always smaller than the total tumour area. The ROI with the maximum average counts in the frame representing the time between 35 and 40 min of the dynamic study was selected to represent the \(^{11}\)C-methionine uptake in the tumour in the analysis of the standardised uptake value (SUV). The respective time activity curve was used in the kinetic analysis.

**Kinetic analysis**

A graphical approach according to Patlak was used to analyse the irreversible \(^{11}\)C-methionine uptake in the tumour tissue (Patlak et al., 1983). In this method normalised plasma time values are plotted on the horizontal and the tissue activity values divided by plasma activity values on the vertical axis:

\[
x(T) = \frac{T}{C_{p}(t)} \int_0^T C_{I}(t) \, dt / C_{I}(T)
\]

\[
y(T) = C_{p}(t) / C_{I}(T)
\]

where \(C_{p}(t)\) is the plasma radioactivity concentration of the tracer at time \(t\), \(T\) is the frame mean time after injection and \(C_{I}(T)\) is the tracer concentration of tumour tissue at time \(T\). When \(y(T)\) is plotted against \(x(T)\) a straight line with a slope of \(K_i\) (influx constant) is obtained. The slope represents the accumulation rate of the tracer from the plasma to the irreversible tissue compartment. The influx constant was calculated from the regression line obtained from seven to ten data points in the straight line of the Patlak plot representing the evaluation time between 11 min to 40 min after the injection. The last frames between 40–60 min post injection were omitted because the tissue time activity curve gradually decreased after 40 min in one study (Leskinen-Kallio et al., 1992a).

**Standardised uptake values (SUV)**

Radioactivity concentration in the tumour ROI per dose corrected by body weight, the standardised uptake value (SUV), was calculated for each patient according to the following formula (Oldendorf, 1974; Woodard et al., 1975; Strauss & Conti, 1991):

\[
SUV = \frac{ROI\, radioactivity\, concentration\, [Bq/ml]}{Injected\, dose\, [Bq] / patient\, weight\, [g]}
\]

The ROIs representing the frametimes between 35 and 40 min were selected for SUV analysis. The uptake of \(^{11}\)C-methionine was assessed without knowledge on the clinical response.

**Results**

The soft tissue metastases of all the eight breast cancer patients were clearly visualised with \(^{11}\)C-methionine (Figure 1). The uptake of \(^{11}\)C-methionine was rapid and achieved a plateau in 10 to 15 min (Figure 2). When the radioactivity concentration of the low molecular weight fraction of plasma was used as an input function in the graphical analysis according to Patlak, a straight line was obtained in the plot at 11 min after injection. The line was straight in all studies from 25 to 40 min, and the influx constant was calculated of seven to ten data points of this period (Figure 3).

A partial remission was seen in three cases (Table II). The Ki decreased in two of these cases (a decrease of 48% and of 15%) and remained the same in the remaining case (a decrease of 2%). Of the five cases with progressive disease, the Ki increased in four (an increase of 12%, 15%, 19% and 68%) and decreased slightly in one metastasis (a decrease of 5%) (Table II). The SUVs of all metastases that responded to the therapy decreased, increased in three and remained the same in two of the five metastases that progressed during treatment (Table III). The greatest difference between the two uptake values was observed in a responding pulmonary metastasis that was studied after a 13 week interval (patient 3).

The uptake rate (Ki) before the start of the new therapeutic modality ranged from 0.035 to 0.186 min\(^{-1}\) and the SUV from 2.5 to 11.4, respectively. The Ki measured during the therapy ranged between 0.030 and 0.143 min\(^{-1}\) and the SUV between 2.0 and 7.8. The highest uptake of \(^{11}\)C-methionine was measured in a pulmonal metastasis, where the Ki was 0.186 min\(^{-1}\) and the SUV 11.4 (patient 3). This patient experienced a long lasting, strong partial response to tamoxifen treatment, and she is surviving after 2 years of the PET studies. No correlation was obtained between the number of previous therapeutic intentions, or rapidity of progression of the disease, and the uptake rate of \(^{11}\)C-methionine.

There was a good correlation between the Ki and SUV in this series (\(r = 0.86, P < 0.0001, n = 16\) (Figure 4).
11C-METHIONINE AND PET IN BREAST CANCER

Figure 1 A pulmonary metastasis of breast cancer in the right hilar region imaged by 11C-methionine and PET (Patient 3).

Figure 2 A typical time activity curve for 11C-methionine activity in a breast cancer metastasis during the PET study (Patient 3).

| Table II | The input corrected uptake values $K_i$ (I) before the onset of the treatment and during the treatment $K_i$ (II) |
|----------|----------------------------------------------------------------------------------------------------------|
| Patient  | $K_i$ (I) $\text{min}^{-1}$ | $K_i$ (II) $\text{min}^{-1}$ | Clinical response | Time interval between PET studies (weeks) |
| 1.       | 0.065                                             | 0.063                                       | PR             | 7                                           |
| 2.       | 0.048                                             | 0.080                                       | PD             | 14                                          |
| 3.       | 0.186                                             | 0.096                                       | PR             | 13                                          |
| 4.       | 0.067                                             | 0.072                                       | PD             | 6                                           |
| 5.       | 0.120                                             | 0.143                                       | PD             | 7                                           |
| 6.       | 0.052                                             | 0.066                                       | PD             | 7                                           |
| 7.       | 0.088                                             | 0.083                                       | PD             | 3                                           |
| 8.       | 0.035                                             | 0.030                                       | PR             | 7                                           |

$P = \text{partial response, } PD = \text{progressive disease.}$

| Table III | The standardised uptake value before the onset of the treatment SUV(I) and during the treatment SUV (II) |
|-----------|------------------------------------------------------------------------------------------------------|
| Patient   | SUV(I) | SUV(II) | Clinical response | Time interval between PET studies (weeks) |
| 1.         | 5.6    | 5.0     | PR               | 7                                          |
| 2.         | 3.8    | 6.2     | PD               | 14                                         |
| 3.         | 11.4   | 7.4     | PR               | 13                                         |
| 4.         | 3.8    | 4.1     | PD               | 6                                          |
| 5.         | 4.6    | 7.8     | PD               | 7                                          |
| 6.         | 5.2    | 5.9     | PD               | 7                                          |
| 7.         | 4.4    | 4.3     | PD               | 3                                          |
| 8.         | 2.5    | 2.0     | PR               | 7                                          |

$P = \text{partial response, } PD = \text{progressive disease.}$
Discussion

In our study, all breast cancer soft tissue metastases had a clear uptake of $^{11}$C-methionine. In three of the five progressing metastases the uptake values increased and remained the same in two, and decreased in all the three regressing metastases.

In one of the cases (patient 7, Table II) the interval between the two PET studies was short, only three weeks, and there was no change in the $K_i$ or in the SUV. At least this reflects good reproducibility of the PET method.

Clinical response to anticancer therapy in breast cancer is usually not evaluable until in 2 to 3 months. There are several therapeutic modalities, and there is an increasing need for predictive methods for treatment response. A rapid and reliable method for evaluation of long-term treatment response would be of value e.g. in chemotherapy, which may cause severe side effects. Estrogen and progesterone receptor content and expression of epidermal growth factor receptors are predictors of endocrine therapy response (Nicholson, 1989), but they may fail in a significant proportion of cases. Assessing tumour amino acid metabolism by $^{11}$C-methionine and PET may provide a more effective predictive method for evaluating individual treatment response.

$^{11}$C-methionine has formerly been reported to be an effective tracer to image gliomas, lung cancer, lymphomas and breast cancer with PET (Derlon et al., 1989; Fujiwara et al., 1989; Leskinen-Kallio et al., 1991a; Leskinen-Kallio et al.,...
The uptake of \( ^{11} \)C-methionine may be associated with the malignancy grade of these tumours (Leskinen-Kallio et al., 1991 a and 1992b). A positron emission tomography method according to Patlak (Patlak et al., 1983) has been applied to \( ^{11} \)C-methionine PET tumour studies by Bergström et al. (1986). Hatazawa et al. (1989) and ourselves (Leskinen-Kallio et al., 1991a). As an input function we used the radioactivity concentration of the low molecular weight fraction of plasma, which consists mainly of \( ^{11} \)C-methionine and not its metabolites (Lundqvist et al., 1985). A straight line was obtained in the plot during 11 to 40 min of the study. This represents the irreversible uptake of \( ^{11} \)C-methionine in plasma to the cancer tissue. This method requires 40 min emission scanning time, several blood samples, and the separation of the low molecular weight fraction of the plasma by fast gel filtration or measuring the \( ^{11} \)C-methionine concentration by high pressure liquid chromatography. In this material, there was an excellent correlation between the SUVs and \( k_s \). For SUV analysis, only 5 to 10 min emission scanning time is needed 20 to 30 min after injection. SUV analysis seems to be an adequate method for clinical PET studies with \( ^{11} \)C-methionine in breast cancer (Leskinen-Kallio et al., 1992a).

In measuring the accumulation of \( ^{11} \)C-methionine in the tumour several factors may affect the ultimate count detected. The differences in the tumour blood flow (Abe et al., 1990), physiological circumstances such as the body temperature, the location of the tumour in the field and the complex metabolism of methionine (Hoffman, 1984) should be bear in mind when interpreting the results of PET studies. The error marginal in PET studies is approximately 5% (Spinks et al., 1988). Minimising these errors and providing the quality and reproducibility of PET studies needs strict standardisation of the study protocol and regular normalisation and calibration of the scanner.

Breast cancer metastases even with the diameter of 2 cm can be imaged with \( ^{11} \)C-methionine and PET. An increase in the uptake of \( ^{11} \)C-methionine 6 to 7 weeks after the beginning of anticancer therapy may predict poor response. Further studies with a larger patient material are needed. Different scanning intervals need to be tested to get more information about changes in amino acid metabolism in breast cancer metastases, and the value of PET in evaluating the treatment response.

We would like to thank Professor Eeva Nordman and Professor Uno Wegelius for their support, Dr Heikki Joensuu for his valuable remarks and the personnel of Nuclear Medicine Department for pleasant cooperation.

References

ABE, Y., MATSUZAWA, T., FUJIIWARA, T., ITOH, M., FUKUDA, H., YAMAGUCHI, K., KUBOTA, K., HATAZAWA, J., TADA, M., IDO, T. & WATANUKI, S. (1990). Clinical assessment of therapeutic effects on cancer using \( 18 \)F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 19, 1005–1010.

BERGSTROM, M., MUHR, C., LUNDBERG, P.O., BERGSTROM, K., GEE, A.D., FASTH, K.-J. & LÅNGSTRÖM, B. (1987). Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study. J. Comput. Assist. Tomogr., 11, 815–918.

BERGSTROM, M., MUHR, C., LUNDBERG, P.O., BERGSTROM, K., GEE, A.D. & FASTH, K.-J. (1986). Amino acid metabolism in pituitary adenomas. Acta Radiol., (suppl), 412–414.

DERLON, J.-M., BOURDET, C., BUSTANY, P., CHATEL, M., THERON, J., DARCEL, E. & SYROTA, A. (1989). \( [11\)C]-Methionine uptake in clinical PET studies. Nucl. Med., 25, 720–728.

FUJIIWARA, T., MATSUZAWA, T., KUBOTA, K., ABE, Y., ITOH, M., FUKUDA, H., HATAZAWA, J., YOSHIOKA, S., YAMAGUCHI, K., ITO, K., WATANUKI, S., TAKAHASI, T., ISHIKAWA, K., IWATA, R. & IDO, T. (1989). Relationship between histologic type of primary lung cancer and carbon-11-l-methionine uptake with positron emission tomography. J. Nucl. Med., 30, 33–37.

HATAZAWA, J., ISHIKAWA, K., ITOH, M., KAMEYAMA, M., KUBOTA, K., IDO, T., MATSUZAWA, T., YOSHIMOTO, T., WATANUKI, S. & SCHOE, S. (1989). Quantitative evaluation of L-methyl-C-\( ^{11} \)methionine uptake in tumour using positron emission tomography. J. Nucl. Med., 30, 1809–1813.

HOFMANN, R.M. (1990). Unbalanced transmethylaion and the permeation of the differentiated state leading to cancer. BioEssays, 12, 163–166.

KUBOTA, K., MATSUZAWA, T., ITO, M., ITO, K., FUJIIWARA, T., ABE, Y., YOSHIOKA, S., FUKUDA, H., HATAZAWA, J., IWATA, R., WATANUKI, S. & IDO, T. (1985). Lung tumor imaging by positron emission tomography using C-11-l-methionine. J. Nucl. Med., 26, 37–42.

KUBOTA, K., MATSUZAWA, T., TAKAHASHI, T., FUJIIWARA, T., KINOMURA, I., IDO, T., SATO, T., KUBOTA, R., TADA, M. & ISHIKAWA, K. (1989). Rapid and sensitive response of carbon-11-l-methionine tumor uptake to irradiation. J. Nucl. Med., 30, 2012–2016.

LESKINEN-KALLO, S., RUOTSALAINEN, U., NÄGREN, K., TERÄS, M. & JOENSUU, H. (1991a). Uptake of \( [11\)C]methionine and FDG in non-Hodgkin’s lymphoma: a PET study. J. Nucl. Med., 32, 1211–1218.

LESKINEN-KALLO, S., NÄGREN, K., LEHIKOINEN, P., RUOTSALAINEN, U. & JOENSUU, H. (1991b). Uptake of \( [11\)C]methionine in breast cancer studied by PET. Br. J. Cancer, 64, 1121–1124.

LESKINEN-KALLO, S., HUOVINEN, R., NÄGREN, K., LEHIKOINEN, P., RUOTSALAINEN, U., TERÄS, M. & JOENSUU, H. (1992a). Methods of \( [11\)C]methionine quantitation in cancer PET studies. J. Comput. Assist. Tomogr., 16, 468–474.